94205-21-7

Upstream product

• 93654-27-4 6-chloro-2-oxo-4-phenyl-1,2-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 4016-85-7 5-chloro-2-(chloroacetylamino)benzophenone 
• 23864-26-8 6-chloro-2-hydroxy-4-phenyl-quinoline-3-carbonitrile 
• 847617-82-7 N-(2-benzoyl-4-chloro-phenyl)-malonamic acid methyl ester 
• 719-59-5 5-chloro-2-aminobenzophenone 
• 284663-87-2 6-chloro-2-oxo-4-phenyl-1,2-dihydro-quinoline-3-carboxylic acid methyl ester 

Downstream Products

• 835882-13-8 6-chloro-2-oxo-4-phenyl-1,2-dihydro-quinoline-3-carboxylic acid chloride 
• 1433903-58-2 N'-(2,6-dichloro-4-phenyl-quinoline-3-carbonyl)-hydrazinecarboxylic acid 9H-fluoren-9-ylmethyl ester 
• 1433903-59-3 6-chloro-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid hydrazide 
• 1433902-27-2 5-(6-chloro-4-phenyl-2-piperidin-1-yl-quinolin-3-yl)-3H-[1,3,4]oxadiazol-2-one 
• 1433902-35-2 5-(6-chloro-4-phenyl-2-piperidin-1-yl-quinolin-3-yl)-3H-[1,3,4]oxadiazole-2-thione 
• 835882-13-8 6-chloro-2-hydroxy-4-phenyl-quinoline-3-carbonyl chloride 

Relevant academic research and scientific papers

Synthesis and biological evaluation of dihydroquinoline carboxamide derivatives as anti-tubercular agents

Sodium trifluoromethanesulfonate, and glacial acetic acid selectively catalyzed the synthesis of dihydroquinoline via Friedl?nder annulation. The synthesized dihydroquinoline analogues coupled with different amines by the use of coupling reagent gave dihy

Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors

Dual inhibition of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) is expected to provide beneficial effects on a number of metabolic parameters such as insulin sensitivity and blood glucose levels and should protect against atherosclerosis. Starting from a FABP4 selective focused screening hit, biostructure information was used to modulate the selectivity profile in the desired way and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. With very good pharmacokinetic properties and no major safety alerts, compound 12 was identified as a suitable tool compound for further in vivo investigations.

METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.

Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma

The protein Kinase B alpha (AKT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways are central regulators of cellular signaling events at the basis of tumor development and progression. Both pathways are often up-regulated in different tumor types including melanoma. We recently reported the identification of compound 1 (BI-69A11) as inhibitor of the AKT and the NF-κB pathways. Here, we describe SAR studies that led to novel fluorinated derivatives with increased cellular potency, reflected in efficient inhibition of AKT and IKKs. Selected compounds demonstrated effective toxicity on melanoma, breast, and prostate cell lines. Finally, a representative derivative showed promising efficacy in an in vivo melanoma xenograft model. We describe SAR studies that led to compound 42 as a potent cellular inhibitor of phosphorylation of AKT1-3 and the NF-κB pathway in melanoma, breast, and prostate cell lines and showed remarkable efficacy in an in vivo melanoma xenograft model with the drug administered orally.

NEW ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.

ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.

QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formulae I and II: (I) (II) wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Synthesis of 2,3,4,6-tetrasubstituted quinolines from 5-substituted 2-chloroacetylaminobenzophenones

Cyclization of 5-substituted 2-chloroacetylaminobenzophenones by the action of NaCN or NaNO2 in dimethylformamide or dimethyl sulfoxide yields 6-substituted 4-aryl-2-hydroxy-3-cyano(nitro)quinolines. Heating of 3-cyanoquinoline derivatives in 75% H2SO4 gives 2-hydroxyquinoline-3-carboxylic acids which can be converted into the corresponding acyl chlorides and then to esters, hydrazides, and amides.

Solid phase synthesis of substituted quinolin-2(1H)-one-3-carboxylic acids via an intramolecular knoevenagel condensation

A solid phase synthesis of substituted quinolin-2(1H)-one-3-carboxylic acids is described. The products are formed in a two-step synthesis in which ortho-aminophenones are first coupled to malonic acid bound to the Wang Resin followed by ring closure via an intramolecular Knoevenagel condensation.